Mon, Oct 20, 2014, 7:07 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Trius Therapeutics, Inc. (TSRX) Message Board

  • leerichs leerichs Jun 8, 2013 1:42 PM Flag

    Interesting article - response to aricle in New York Times

    Developing New Antibiotics

    June 7, 2013

    To the Editor:

    In “Pressure Grows to Create Drugs for ‘Superbugs’ ” (front page, June 3), Dr. Janet Woodcock of the Food and Drug Administration notes that the antibiotics pipeline is so thin that we face “a huge crisis worldwide.”

    Recent legislation providing incentives for the development of antibiotics is an important step but will likely have limited impact. The unmentioned and perhaps larger issue is that many, including physicians, insurers and pharmacists, expect antibiotics, which may cure us of a potentially fatal infection, to be virtually free. In contrast, treatments for cancer, which may extend life for a few months but not cure patients, commonly command prices of tens of thousands of dollars.

    Critics of incentives to antibiotic developers often cite safety concerns and the risk that rapid development pathways may result in the overuse of new treatments. This misses the point. In fact, it is the absence of market incentives that drives the abandonment of antibiotic development, the overuse of cheap generics and the consequent resistance crisis we face today.

    JEFFREY STEIN
    San Diego, June 6, 2013

    The writer is president and chief executive of Trius Therapeutics, a biopharmaceutical company.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
TSRX
13.630.00(0.00%)Sep 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.